M. Royce Et Al. , "BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)," 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , vol.27, Copenhagen, Denmark, 2016
Royce, M. Et Al. 2016. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC). 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , (Copenhagen, Denmark).
Royce, M., Villanueva, C., Ozguroglu, M., Bachelot, T., Azevedo, S., Melo Cruz, F., ... Hegg, R.(2016). BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) . 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark
Royce, M. Et Al. "BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)," 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 2016
Royce, M. Et Al. "BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)." 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , Copenhagen, Denmark, 2016
Royce, M. Et Al. (2016) . "BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)." 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , Copenhagen, Denmark.
@conferencepaper{conferencepaper, author={M. Royce Et Al. }, title={BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)}, congress name={41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO)}, city={Copenhagen}, country={Denmark}, year={2016}}